The FDA has approved Ngenla (somatrogon-ghla), a new once-weekly human growth hormone analog, for treating growth failure in children aged 3 years and older who do not produce enough growth hormone. This condition, called growth hormone deficiency, can slow a child's growth and lead to shorter adult height. Ngenla is given as a shot once a week, unlike older treatments that require daily injections. This less frequent dosing may make it easier for children and families to stick with the treatment.
The approval was based on a study of 224 children who had not been treated before. After one year, children taking Ngenla grew about 10.1 centimeters per year, similar to the 9.8 centimeters per year seen with daily growth hormone shots. This shows that Ngenla works as well as the daily option.
Before starting Ngenla, your child will need an eye exam to check for a condition called papilledema, which is swelling in the back of the eye. The dose will be adjusted based on how your child responds to treatment.
If you think your child might benefit from Ngenla, talk to your doctor. They can help you understand if this new option is right for your child and how it compares to other treatments.